CPT code 91322 identifies a SARS–CoV–2 vaccine product administered intramuscularly at a dosage of 50 mcg/0.5 mL to reduce risk of COVID–19. This vaccine code matters nationally as COVID–19 vaccination remains a central public health activity with broad payer coverage and implications for outpatient care delivery, reporting, and vaccine inventory management.

Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context, typical sites of service, and payer scope. The publication summarizes common modifier usage patterns and highlights areas where payers have historically issued policy guidance or coverage criteria for vaccine administration services. It also outlines benchmarks and policy updates relevant to billing and reimbursement for adult and eligible population vaccination programs.

The report is intended to help billing managers, compliance officers, and clinicians understand how CPT code 91322 is used in practice, what services it represents, and where to look for payer-specific policy details. Data not available in the input for associated taxonomies, ICD-10 diagnoses, and related codes.